View Author
patient treatment hepatitis study response liver hepatitis c group therapy disease t-cell brosi signi result fi brosis netherland level liver fi brosis analysis ribavirin center hepatitis c virus serum virus amantadine signi ficantly hepatology baseline cirrhosis table hcv-speci gastroenterology infection lsm results genotype remission cholestasi load decrease effect pruritu university disorder ficant interferon difference biliary pancreatitis mycophenolate mofetil biopsy factor assay range department control criteria survival number lsm 1 biliary cirrhosis value figure utrecht syndrome 1 year measurement bilirubin hcv mono-infected patients fi rst phase decrease center utrecht hcv /hiv patients placebo mycophenolate failure expression overlap activity complication outcome mono-infected
10 Most Recent Publications
|
Mycophenolate mofetil for patients with autoimmune hepatitis and overlap syndromes: Authors' reply
(Article)
Baven-Pronk, A.M.C. Coenraad, M.J. Koek, G.H. Nieuwkerk, C.M.J. van Bouma, G. Brouwer, J.T. Hoek, B. van Buuren, H.R. van Man, R.A. de Erpecum, K.J. van Lamers, M.M.H. Drenth, J.P.H. Berg, A.P. van den Beuers, U. Ouden, J. den |
2011-09-01
|
|
Liver stiffness measurements to assess progression of fibrosis in HCV-infected patients with inherited bleeding disorders
(Article)
Fransen van de Putte, D.E. Fischer, K. Knegt, R.J. de Posthouwer, D. Erpecum, K.J. van Mauser-Bunschoten E. |
2011-09-01
|
|
Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease
(Article)
Nijmeijer, R.M. Gadaleta, R.M. Weersma, R.K. Woude, C.J. van der Stapelbroek, J.M. Schipper, M.E.I. Wijmenga, C. Erpecum, K.J. van Oldenburg, B. Mil, S.W.C. van Bodegraven, A.A. van Crusius, J.B.A. Dijkstra, G. Hommes, D.W. Jong, D.J. de Stokkers, P.C.F. Verspaget, H.W. |
2011-08-26
|
|
The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes
(Article)
Baven-Pronk, A.M.C. Coenraad, M.J. Koek, G.H. Nieuwkerk, C.M.J. van Bouma, G. Brouwer, J.T. Hoek, B. van Buuren, H.R. van Man, R.A. de Erpecum, K.J. van Lamers, M.M.H. Drenth, J.P.H. Berg, A.P. van den Beuers, U. Ouden, J. den |
2011-07-01
|
|
T-cell responses at baseline and during therapy with peginterferon-α and ribavirin are not associated with outcome in chronic hepatitis C infected patients
(Article)
Arends, J.E. Claassen, M.A.A. Berg, C.H.S.B. van den Nanlohy, N.M. Erpecum, K.J. van Baak, B.C. Hoepelman, I.M. Boonstra, P.A. Baarle, D. van |
2010-09-01
|
|
Lysophosphatidic acid is a potential mediator of cholestatic pruritus
(Article)
Kremer, A.E. Martens, J.J.W.W. Geenes, V.L. Williamson, C. Moolenaar, W.H. Beuers, U. Oude Elferink, R.P.J. Kulik, W. Rueff, F. Kuiper, E.M.M. Buuren, H.R. van Erpecum, K.J. van Kondrackiene, J. Prieto, J. Rust, C. |
2010-09-01
|
|
No beneficial effects of amantadine in treatment of chronic hepatitis C patients
(Article)
Soest, H. van Schaar, P.J. van der Sluys Veer, A. van der Siersema, P.D. Schipper, M.E.I. Erpecum, K.J. van Boland , G.J. Koek, G.H. Vries, R.A. de Ooteghem, N.A. Hoek, B. van Drenth, J.P.H. Vrolijk, J.M. Lieverse, R.J. Houben, P. |
2010-07-01
|
|
Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCVHIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2aribavirin therapy
(Article)
Arends, J.E. Stuart, J.C. Baak, L.C. Ende, M.E. van der Erpecum, K.J. van Simons, C.P.M. Boland , G.J. Baarle, D. van Hoepelman, I.M. |
2009-12-01
|
|
Early endoscopic retrograde cholangiopancreatography in predicted severe acute biliary pancreatitis: A prospective multicenter study
(Article)
Santvoort, H.C. van Besselink, M.G. Dejong, C.H. Eijck, C.H.J. van Witteman, B.J.M. Weusten, B.L. Laarhoven, C.J. van Wahab, P.J. Tan, A.C. Schwartz, M.P. Harst, E. van der Cuesta, M.A. Vries, A.C. de Siersema, P.D. Gooszen, H.G. Erpecum, K.J. van Ramshorst, B. van Timmer, R. Kruyt, Ph.M. Brink, M.A. Mundt, M. Frankhuisen, R. Consten, E.C. Boermeester, M.A. Nooteboom, A. Jansen, J.B. Bongaerts, G.T. Buscher, H.C. Rosman, C. Ootes, L. Houben, B. Ahmed Ali, U. Zeguers, V. Roeterdink, A. Fischer, K. Rijnhart, H.G. Leeuwen, M.S. van Haasnoot, A. Rutten, J.P. Dam, R. van Drixler, T.A. Spillenaar Bilgen, E.J. Embden, P. van Ruler, O. van Gouma, D.J. Bollen, T.L. Bruno, M.J. Hofker, H.S. Ploeg, R.J. Kruijt Spanjer, M.R. Buitenhuis, H.T. Vliet, S.U. van Ramcharan, S. Lange, J.F. Wijffels, N.A. Walraven, L.A. van Cirkel, G.A. Kubben, F.J. Wal, J.B.C. van der Hof, G. van't Kuipers, E.J. Poley, J.W. Schaapherder, A.F.M. Nieuwenhuijs, V.B. Goor, H. van |
2009-07-01
|
|
Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid
(Article)
Kuiper, E.M.M. Hansen, B.E. Vries, R.A. de Ouden-Muller, J.W. den Ditzhuijsen, T.J.M. van Haagsma, E.B. Houben, M.H.M.G. Witteman, B.J.M. Erpecum, K.J. van Buuren, H.R. van |
2009-04-01
|
